: As of early 2026, DiscGenics has treated the first patient in its pivotal Phase 3 study. This study targets approximately 162 subjects with mild-to-moderate lumbar DDD at levels L3–S1.
Regenerative strategies for intervertebral disc degeneration diskgen intervertebral
The therapy is currently in late-stage clinical evaluation in the United States. : As of early 2026, DiscGenics has treated
Enter the age of motion preservation.
: Unlike palliative treatments that only mask pain, IDCT uses a proprietary population of live Discogenic Cells —progenitor cells derived from donated adult human disc tissue. These cells are injected into the degenerated disc to reduce inflammation and potentially restore disc structure from within. Enter the age of motion preservation
DiskGen refers to a category or specific brand of designed to replace a damaged natural disc while maintaining the spine's natural range of motion.